China Sinopharm's potential COVID-19 vaccine triggers antibodies in clinical trials: journal

BEIJING (Reuters) - A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.

The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.

Sinopharm is testing the potential vaccine in the...